Timothy Stonesifer Buys 2,790 Shares of Insulet (NASDAQ:PODD) Stock

Posted by George Bondi on Jun 4th, 2026

Insulet Corporation (NASDAQ:PODD – Get Free Report) Director Timothy Stonesifer bought 2,790 shares of Insulet stock in a transaction dated Wednesday, June 3rd. The shares were purchased at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the transaction, the director owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. This represents a 44.63% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Insulet Stock Up 2.2%

Shares of NASDAQ PODD traded up $3.11 during trading on Thursday, reaching $146.41. 1,409,969 shares of the stock were exchanged, compared to its average volume of 1,181,413. The business’s 50-day moving average price is $178.57 and its 200 day moving average price is $240.82. Insulet Corporation has a twelve month low of $140.63 and a twelve month high of $354.88. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $10.14 billion, a price-to-earnings ratio of 34.05, a price-to-earnings-growth ratio of 1.12 and a beta of 1.13.

Insulet (NASDAQ:PODD – Get Free Report) last posted its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The business had revenue of $761.70 million for the quarter, compared to analysts’ expectations of $729.89 million. During the same period in the previous year, the company posted $1.02 earnings per share. The business’s revenue for the quarter was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, equities analysts forecast that Insulet Corporation will post 6.44 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Wall Street Zen raised shares of Insulet from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Robert W. Baird dropped their target price on shares of Insulet from $360.00 to $248.00 in a research report on Thursday, May 7th. JPMorgan Chase & Co. dropped their target price on shares of Insulet from $340.00 to $275.00 and set an “overweight” rating for the company in a research report on Thursday, May 7th. Jefferies Financial Group dropped their target price on shares of Insulet from $400.00 to $360.00 in a research report on Thursday, May 7th. Finally, Piper Sandler dropped their target price on shares of Insulet from $360.00 to $210.00 in a research report on Wednesday, May 6th. Twenty-one investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Insulet currently has a consensus rating of “Moderate Buy” and a consensus price target of $252.04.

Read Our Latest Report on PODD

Institutional Trading of Insulet

Institutional investors and hedge funds have recently modified their holdings of the business. Larson Financial Group LLC raised its holdings in shares of Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 47 shares during the period. University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Insulet during the fourth quarter worth $26,000. Elyxium Wealth LLC acquired a new stake in shares of Insulet during the fourth quarter worth $28,000. DV Equities LLC acquired a new stake in shares of Insulet during the fourth quarter worth $28,000. Finally, MV Capital Management Inc. acquired a new stake in shares of Insulet during the fourth quarter worth $29,000.

About Insulet

(Get Free Report)

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.